Search

Search Results

• 

  Evaluation of Th9 lymphocytes in peripheral blood of rheumatoid arthritis patients and correlation with anti-tumor necrosis factor therapy: results from an in vitro pivotal study

  R. Talotta, A. Berzi, F. Atzeni, D. Dell'Acqua, P. Sarzi Puttini, D. Trabattoni

  83-89

  09-09-2016

  https://doi.org/10.4081/reumatismo.2016.875

  1966

  PDF: 975

  IL RUOLO DEI LINFOCITI TH9 NELL'ARTRITE REUMATOIDE E NELLA RISPOSTA AL TRATTAMENTO CON INFLIXIMAB.: 558

• Incidence and management of infusion reactions to infliximab in 186 italian patient’s with rheumatoid arthritis: the Padua experience

  C. Botsios, P. Ostuni, S. Todesco

  44-51

  https://doi.org/10.4081/reumatismo.2005.44

  1205

  PDF: 1788

• Long-term evaluation of infliximab in the treatment of persistently active juvenile idiopathic arthritis refractory to conventional therapy

  G. De Marco, V. Gerloni, I. Pontikaki, A. Lurati, B. Teruzzi, A. Salmaso, E. Valcamonica, M. Gattinara, F. Fantini

  50-56

  https://doi.org/10.4081/reumatismo.2007.50

  1206

  PDF: 847

• Antinuclear, anti-dsDNA and anti-ENA antibodies in patients affected with rheumatoid arthritis or ankylosing spondylitis during treatement with infliximab

  A. Hoxha, A. Ruffatti, P. Grypiotis, M. Podswiadek, C. Botsios, U. Fiocco, L. Punzi, S. Todesco

  121-126

  https://doi.org/10.4081/reumatismo.2006.121

  1882

  PDF: 1751
• 

  A false occult hepatitis B virus infection developed in a patient with psoriatic arthritis under infliximab and methotrexate therapy

  A. Notarnicola, F. Iannone, G. Lopalco, M. Covelli, G. Lapadula

  298-301

  17-03-2014

  https://doi.org/10.4081/reumatismo.2013.727

  2467

  PDF: 1128
• 

  Predictive factors for partial remission according to the Ankylosing Spondylitis Assessment Study working group in patients with ankylosing spondylitis treated with anti-TNFα drugs

  F.M. Perrotta, O. Addimanda, R. Ramonda, S. D’Angelo, E. Lubrano, A. Marchesoni, I. Olivieri, L. Punzi, C. Salvarani, A. Spadaro

  208-214

  06-11-2014

  https://doi.org/10.4081/reumatismo.2014.756

  2771

  PDF: 1569

• PO:36:243 | Drug survival, discontinuation reasons and disease activity in patients with Behçet's disease treated with infliximab - a real-life study Antonello Sulis¹, Federica Di Cianni¹, Maria Laura Manca², Rosaria Talarico¹, Marta Mosca¹. | ¹Rheumatology Unit of Pisa, University of Pisa, Pisa, Italy, Pisa, Italy; ²Department of Clinical and Experimental Medicine and Department of Mathematics, University of Pisa, Italy, Pisa, Italy.

  Società Italiana di Reumatologia

  26-11-2025

  https://doi.org/10.4081/reumatismo.2025.2091

  64
• 

  Intra-articular therapy with tumor necrosis factor-α antagonists: an update

  S. Bello, C. Bonali, L. Serafino, C. Rotondo, N. Terlizzi, G. Lapadula

  257-263

  14-03-2014

  https://doi.org/10.4081/reumatismo.2013.721

  2699

  PDF: 1287
• 

  Infliximab in the treatment of Budd-Chiari syndrome in Behçet’s disease

  L.B. Santos, J. Rigueira, A.P. Vilas

  163-165

  24-10-2019

  https://doi.org/10.4081/reumatismo.2019.1153

  1472

  PDF: 876
• 

  Infliximab as successful treatment option in a case of adenosine deaminase 2 deficiency

  M.B. Ates, S. Karup, S. Ugurlu

  19-12-2023

  https://doi.org/10.4081/reumatismo.2023.1543

  1426

  PDF: 434

• The treatment of recurrent uveitis with TNFα inhibitors

  P.C.F. Falappone, F. Iannone, C. Scioscia, V. Grattagliano, M. Covelli, G. Lapadula

  185-189

  https://doi.org/10.4081/reumatismo.2004.185

  1826

  PDF: 2448

• Infliximab therapy for Crohn’s disease in the presence of chronic hepatitis C infection - Reply

  M. Galeazzi

  112

  https://doi.org/10.4081/reumatismo.2003.112

  809

  PDF: 630
• 

  Psoriatic arthritis: treatment strategies using biologic agents

  S. D'Angelo, C. Palazzi, I. Olivieri

  113-121

  05-06-2012

  https://doi.org/10.4081/reumatismo.2012.113

  1353

  PDF: 1196
• 

  A short history of anti-rheumatic therapy - VII. Biological agents

  G. Pasero, P. Marson, B. Gatto

  185-194

  09-11-2011

  https://doi.org/10.4081/reumatismo.2011.185

  1604

  PDF: 1276

• PO:02:024 | Development of anti-drug antibodies in patients with peripheral and/or axial spondyloarthritis treated with infliximab or adalimumab: a monocentric cross-sectional study Gabriele Amati¹, Gilda Sandri^1|2, Alessandra Melegari³, Benedetta Bongiovanni^1|2, Giovanni Ciancio², Martina Orlandi^1|2, Ottavio Secchi¹, Dilia Giuggioli^1|2 | ¹Struttura complessa di Reumatologia, Azienda Ospedaliero-Universitaria Policlinico di Modena; ²Cattedra di Reumatologia, Università degli studi di Modena e Reggio Emilia; ³Dipartimento di medicina di laboratorio, Ospedale di Baggiovara, AUSL di Modena, Italy

  Società Italiana di Reumatologia

  26-11-2025

  https://doi.org/10.4081/reumatismo.2025.2126

  75

• Biologic therapy with anti-TNFa in spondyloarthritides and other autoimmune diseases

  G. Lapadula

  22-29

  https://doi.org/10.4081/reumatismo.2005.4s.22

  846

  PDF: 1120
• 

  GISEA: an Italian biological agents registry in rheumatology

  G. Lapadula, G. Ferraccioli, C. Ferri, L. Punzi, F. Trotta

  155-164

  09-11-2011

  https://doi.org/10.4081/reumatismo.2011.155

  2500

  PDF: 1644

• Sustained response to infliximab treatment in two cases of early rheumatoid arthritis that has been maintained after drug withdrawal

  P. Caramaschi, S. Pieropan, A. Volpe, A. Carletto, L.M Bambara, D. Biasi

  221-223

  https://doi.org/10.4081/reumatismo.2008.221

  819

  PDF: 1391

• Polyarthritis flare in patient with ankylosing spondylitis treated with infliximab

  M. Gutierrez, A. Becciolini, C. Bertolazzi, L. Di Geso, M. Tardella, A. Ariani, E. Filippucci, W. Grassi

  221-224

  https://doi.org/10.4081/reumatismo.2010.221

  1242

  PDF: 736

• Case report: AREB in a patient with rheumatoid arthritis treated with methotrexate and infliximab

  Giuseppe D'Alessandro, Maria Rosaria Bianco, Spiridon Politis, Celestino Ferrandina, Giuseppe Rossi, Emanuele Altomare

  59-61

  https://doi.org/10.4081/reumatismo.2006.59

  975

  PDF: 939

• Diffused suberitrodermic psoriasis induced by infliximab

  V. Bruzzese

  328-331

  https://doi.org/10.4081/reumatismo.2007.328

  908

  PDF: 1123

• Intra-articular therapy with infliximab in psoriatic arthritis: efficacy and safety in refractory monoarthritis

  S. Bello, C. Bonali, L. Serafino, P. Di Giuseppe, A. Minosi, N. Terlizzi

  46-50

  https://doi.org/10.4081/reumatismo.2010.46

  1151

  PDF: 1356

• Side effects of anti-TNFa therapy in juvenile idiopathic arthritis

  Irene Pontikaki, Valeria Gerloni, Maurizio Gattinara, Alfredomaria Lurati, Alessandra Salmaso, Gabriele De Marco, Barbara Teruzzi, Elisabetta Valcamonica, Flavio Fantini

  31-38

  https://doi.org/10.4081/reumatismo.2006.31

  1857

  PDF: 2590

• Safety of anti-TNFa biological drugs

  F. Trotta, G. Valentini

  34-39

  https://doi.org/10.4081/reumatismo.2005.4s.34

  1212

  PDF: 1265

• Anakinra, a recombinant human IL-1 receptor antagonist, in clinical practice. Outcome in 60 patients with severe rheumatoid arthritis

  C. Botsios, P. Sfriso, A. Furlan, P. Ostuni, M. Biscaro, U. Fiocco, S. Todesco, L. Punzi

  32-37

  https://doi.org/10.4081/reumatismo.2007.32

  1727

  PDF: 809

• Switching between TNFα antagonists in rheumatoid arthritis: personal experience and review of the literature

  R. Scrivo, F. Conti, F.R. Spinelli, S. Truglia, L. Magrini, M. Di Franco, F. Ceccarelli, G. Valesini

  107-117

  https://doi.org/10.4081/reumatismo.2009.107

  1969

  PDF: 1208

• Approved indications and other possible utilizations of anti-TNFa biologic drugs

  W. Grassi, C. Montecucco

  30-33

  https://doi.org/10.4081/reumatismo.2005.4s.30

  1210

  PDF: 908

• Are there any positive effects of TNF-alpha blockers on bone metabolism?

  B. Seriolo, S. Paolino, A. Sulli, M. Cutolo

  199-205

  https://doi.org/10.4081/reumatismo.2006.199

  1325

  PDF: 1207

• Correlation between radiographic, echographic and MRI changes and rheumatoid arthritis progression

  M.A. Cimmino, M. Parodi, E. Silvestri, G. Garlaschi

  28-40

  https://doi.org/10.4081/reumatismo.2004.1s.28

  1056

  PDF: 2977

• Blocking TNF in vitro with infliximab determines the inhibition of expansion and interferon gamma production of Vγ9/Vδ2 T lymphocytes from patients with active rheumatoid arthritis. A role in the susceptibility to tuberculosis?

  A.R. Giardina, A. Accardo-Palumbo, F. Ciccia, A. Ferrante, A. Principato, R. Impastato, G. Triolo

  21-26

  https://doi.org/10.4081/reumatismo.2009.21

  1487

  PDF: 1155

• Biologic therapy with anti-TNFa in rheumathoid atrhritis

  G. Ferraccioli

  17-21

  https://doi.org/10.4081/reumatismo.2005.4s.17

  802

  PDF: 720

• Analysis of the kinetic of expression of tristetraprolin and HuR by rheumatoid arthritis patients pheripheral blood mononuclear cells stimulated with lipopolysaccharide

  M. Fabris, B. Tolusso, E. Gremese, P. Tomietto, G. Ferraccioli

  94-103

  https://doi.org/10.4081/reumatismo.2004.94

  1421

  PDF: 964
• 

  Development of thymoma without myasthenia gravis in a patient with radiographic axial spondyloarthritis treated with tumor necrosis factor-α inhibitors

  Piera Altieri, Francesco Maria Mariani, Evy Di Ruscio, Francesco Carubbi, Claudio Ferri, Alessia Alunno

  05-06-2025

  https://doi.org/10.4081/reumatismo.2025.1693

  2317

  PDF: 61

• Differences in pharmacology of tumor necrosis factor (TNF) antagonists

  U. Fiocco, S. Bombardieri

  8-16

  https://doi.org/10.4081/reumatismo.2005.4s.8

  1215

  PDF: 1793

• Infections in patients with rheumatoid arthritis receiving anti-cytokine therapy: biological mechanisms and clinical aspects

  C. Botsios, P. Ostuni, P. Sfriso, A. Furlan, U. Fiocco, D. Sgarabotto, S. Todesco

  224-235

  https://doi.org/10.4081/reumatismo.2003.224

  1193

  PDF: 2643

• Recurrent new-onset uveitis in a patient with rheumatoid arthritis during anti-TNFα treatment

  M. Di Gangi, R. Foti, R. Leonardi, C. Leonetti, P. Castellino

  169-172

  https://doi.org/10.4081/reumatismo.2007.169

  1085

  PDF: 1028
• 

  Inflammatory back pain as an unusual manifestation of Takayasu arteritis: a case report

  Faiq Gorial, Nabaa Awadh, Ali Al-Shakarchi, Ghaith Al-Gburi

  30-10-2024

  https://doi.org/10.4081/reumatismo.2024.1678

  1956

  PDF: 353

• Effects of TNF antagonists on immune and neuroendocrine system

  G. Valesini, M. Cutolo

  3-7

  https://doi.org/10.4081/reumatismo.2005.4s.3

  1268

  PDF: 813

• TNF-alpha and insulin-resistance: metabolic effects of in vivo therapeutic blockade

  F. Ursini

  254-259

  https://doi.org/10.4081/reumatismo.2009.254

  1644

  PDF: 2365

• A comparison between the Simplified Disease Activity Index (SDAI) and the Disease Activity Score (DAS28) as measure of response to treatment in patients undergoing different therapeutic regimens

  Giovanna Cuomo, Gabriella Molinaro, Giovanni La Montagna, Sergio Migliaresi, Gabriele Valentini

  22-25

  https://doi.org/10.4081/reumatismo.2006.22

  1597

  PDF: 2053
• 

  Achievement of sustained deep remission with adalimumab in a patient with both refractory ulcerative colitis and seronegative erosive rheumatoid arthritis

  G. Andrisani, E. Gremese, L. Guidi, A. Papa, M. Marzo, C. Felice, D. Pugliese, A. Armuzzi

  75-78

  27-05-2013

  https://doi.org/10.4081/reumatismo.2013.75

  3053

  PDF: 954

• Anti-TNFa treatment in patients with rheumatoid arthritis and anti-Ro/SSA antibodies

  I. Cavazzana, F. Franceschini, E. Danieli, M. Frassi, M. Vianelli, R. Gorla, P. Airò, R. Cattaneo

  267-272

  https://doi.org/10.4081/reumatismo.2005.267

  1129

  PDF: 1777

• Infliximab treatment in a case of rheumatoid scleromalacia perforans

  R. Herrera-Esparza, E. Avalos-Diaz

  212-215

  https://doi.org/10.4081/reumatismo.2009.212

  1251

  PDF: 1023